B celltranslocation gene 1 (BTG1) is a highly conserved gene and recurrently mutated in the MCD subtype of diffuse large B-cell lymphoma (DLBCL). The specific enrichment of BTG1 mutation (BTG1mut) raises a potential hypothesis that they may actively contribute to DLBCL. However, the biological characteristics and prognostic significance of BTG1 in DLBCL remain to be explored. Therefore, the objective of our study was to evaluate the value of BTG1 in DLBCL. The available clinical information and corresponding mutation data of DLBCL were obtained from published articles. Tumor tissue samples of DLBCL patients diagnosed in Jiangsu Province Hospital (JSPH) from 2021 to 2023 were collected for NGS, 195 samples were analyzed the gene expression levels using RNA-seq, among them, 40 samples were analyzed by untargeted metabolomic. We enrolled 2,379 DLBCL patients from 5 published studies and 243 DLBCL patients from Jiangsu Province Hospital (JSPH) cohort. 11.0% (262/2379) of patients were BTG1mut in external cohort, compared with 25.1% (61/243) in the JSPH cohort. BTG1mut was associated with adverse clinical features and was prone to involve testis. Patients with BTG1mut exhibit inferior overall survival (OS). Furthermore, pathway enrichment analysis of the untargeted metabolomic showed that several meaningful pathways have been found such as amino acid metabolism and lipid metabolism. BTG1 mutation was promising prognostic predictor for DLBCL. The mechanism driving different survival outcomes may be attributed to the tumor metabolic reprogramming.
Shang et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: